Foghorn Therapeutics Inc. Comprehensive Income
Foghorn Therapeutics Inc. (FHTX) reported Comprehensive Income of -$7.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- Foghorn Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$7.19M.
- Foghorn Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$20.03M.
- Foghorn Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$21.66M.
- Foghorn Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$15.78M.
- Foghorn Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$74.39M.
- Foghorn Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$85.66M.
- Foghorn Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$95.27M.
- Foghorn Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$112.86M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.19M 10-Q · filed 2026-08-06 | -$27.22M 10-Q · filed 2026-08-06 | -$48.89M derived: sum of 3 quarters · filed 2026-08-06 | -$64.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$20.03M 10-Q · filed 2026-05-07 | -$41.70M derived: sum of 2 quarters · filed 2026-05-07 | -$57.48M derived: sum of 3 quarters · filed 2026-05-07 | -$75.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$21.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$37.45M derived: sum of 2 quarters · filed 2026-03-11 | -$55.44M derived: sum of 3 quarters · filed 2026-08-06 | -$74.39M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$15.78M 10-Q · filed 2025-11-05 | -$33.77M derived: sum of 2 quarters · filed 2026-08-06 | -$52.73M 10-Q · filed 2025-11-05 | -$72.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$17.99M 10-Q · filed 2026-08-06 | -$36.95M 10-Q · filed 2026-08-06 | -$56.68M derived: sum of 3 quarters · filed 2026-08-06 | -$75.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$18.95M 10-Q · filed 2026-05-07 | -$38.68M derived: sum of 2 quarters · filed 2026-05-07 | -$57.11M derived: sum of 3 quarters · filed 2026-05-07 | -$79.93M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$19.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$38.15M derived: sum of 2 quarters · filed 2026-03-11 | -$60.97M derived: sum of 3 quarters · filed 2026-03-11 | -$85.66M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$18.42M 10-Q · filed 2025-11-05 | -$41.24M derived: sum of 2 quarters · filed 2025-11-05 | -$65.93M 10-Q · filed 2025-11-05 | -$88.97M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$22.82M 10-Q · filed 2025-08-05 | -$47.51M 10-Q · filed 2025-08-05 | -$70.55M derived: sum of 3 quarters · filed 2025-08-05 | -$84.06M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$24.69M 10-Q · filed 2025-05-14 | -$47.73M derived: sum of 2 quarters · filed 2025-05-14 | -$61.24M derived: sum of 3 quarters · filed 2025-05-14 | -$90.58M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$23.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$36.56M derived: sum of 2 quarters · filed 2025-03-06 | -$65.89M derived: sum of 3 quarters · filed 2025-03-06 | -$95.27M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$13.52M 10-Q · filed 2024-11-04 | -$42.85M derived: sum of 2 quarters · filed 2024-11-04 | -$72.23M 10-Q · filed 2024-11-04 | -$100.23M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | -$29.34M 10-Q · filed 2024-08-08 | -$58.71M 10-Q · filed 2024-08-08 | -$86.72M derived: sum of 3 quarters · filed 2024-08-08 | -$114.16M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$29.37M 10-Q · filed 2024-05-06 | -$57.38M derived: sum of 2 quarters · filed 2024-05-06 | -$84.82M derived: sum of 3 quarters · filed 2024-05-06 | -$114.13M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | -$28.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$55.45M derived: sum of 2 quarters · filed 2024-03-07 | -$84.76M derived: sum of 3 quarters · filed 2024-03-07 | -$112.86M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$27.44M 10-Q · filed 2023-11-02 | -$56.75M derived: sum of 2 quarters · filed 2023-11-02 | -$84.85M 10-Q · filed 2023-11-02 | -$113.99M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$29.31M 10-Q · filed 2023-08-04 | -$57.41M 10-Q · filed 2023-08-04 | -$86.55M derived: sum of 3 quarters · filed 2023-08-04 | -$112.63M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | -$28.10M 10-Q · filed 2023-05-08 | -$57.24M derived: sum of 2 quarters · filed 2023-05-08 | -$83.32M derived: sum of 3 quarters · filed 2023-05-08 | -$106.45M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$29.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$55.22M derived: sum of 2 quarters · filed 2023-03-09 | -$78.35M derived: sum of 3 quarters · filed 2023-03-09 | -$101.32M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$26.08M 10-Q · filed 2022-11-08 | -$49.21M derived: sum of 2 quarters · filed 2022-11-08 | -$72.18M 10-Q · filed 2022-11-08 | -$92.95M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$23.13M 10-Q · filed 2022-08-09 | -$46.10M 10-Q · filed 2022-08-09 | -$66.86M derived: sum of 3 quarters · filed 2022-08-09 | -$85.23M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$22.97M 10-Q · filed 2022-05-09 | -$43.74M derived: sum of 2 quarters · filed 2022-08-09 | -$62.10M derived: sum of 3 quarters · filed 2022-08-09 | -$77.83M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | -$20.77M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | -$39.13M derived: sum of 2 quarters · filed 2022-08-09 | -$54.85M derived: sum of 3 quarters · filed 2022-08-09 | -$68.81M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | -$18.37M 10-Q · filed 2021-11-09 | -$34.09M derived: sum of 2 quarters · filed 2021-11-09 | -$48.04M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$15.72M 10-Q · filed 2021-08-10 | -$29.68M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$13.95M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | -$51.13M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |